FINGOLIMOD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fingolimod, and when can generic versions of Fingolimod launch?
Fingolimod is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Apotex, Aurobindo Pharma Ltd, Biocon Ltd, Bionpharma, Chartwell Rx, Dr Reddys, Ezra Ventures, Glenmark Pharms Ltd, Hec Pharm Co Ltd, Hetero Labs Ltd V, Mylan, Prinston Inc, Sun Pharm, Teva Pharms Usa, and Zydus Pharms. and is included in eighteen NDAs.
The generic ingredient in FINGOLIMOD is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fingolimod
A generic version of FINGOLIMOD was approved as fingolimod hydrochloride by BIOCON LTD on December 4th, 2019.
Summary for FINGOLIMOD
US Patents: | 0 |
Applicants: | 17 |
NDAs: | 18 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for FINGOLIMOD |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FINGOLIMOD |
DailyMed Link: | FINGOLIMOD at DailyMed |
Recent Clinical Trials for FINGOLIMOD
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Methodist Hospital Research Institute | Phase 2 |
General Hospital of Shenyang Military Region | Phase 4 |
Hoffmann-La Roche | Phase 3 |